Drugs · acquisition-cost intelligence
KLOR-CON
potassium chloride· ingredient potassium chlorideElectrolyte solutions· POTASSIUM CHLORIDE 10 meq/1; POTASSIUM CHLORIDE 600 mg/1; POTASSIUM CHLORIDE 750 mg/1; POTASSIUM CHLORIDE 8 meq/1
What this is. Acquisition-cost intelligence for pharmacy & clinic buyers — the historical trend, generic-equivalent costs, and Part D posture. NADAC is a pharmacy acquisition cost (the national average pharmacies pay), not a retail or cash price — for consumer cash prices use GoodRx/your plan.
Acquisition benchmark · NADAC per EA
$0.08823
NADAC — pharmacy acquisition cost, not a retail/cash price
Acquisition-cost history
Weekly NADAC per EA — the trend nobody else shows. 10 weeks.
2025-07-232026-05-20
Same-ingredient options by acquisition cost
Other potassium chloride products, cheapest acquisition cost first. Per EA — confirm strength/form equivalence before switching.
| Product | NADAC / EA | vs this |
|---|---|---|
| POTASSIUM CHLORIDE | $0.04117 | −$0.04710 |
| Potassium Chloride Extended-Release | $0.08823 | +$0.00000 |
| Potassium chloride extended release | $0.08823 | +$0.00000 |
| POTASSIUM CHLORIDE EXTENDED RELEASE | $0.13526 | +$0.04700 |
| KLOR-CON M | $0.13670 | +$0.04850 |
| KLOR-CON M | $0.13803 | +$0.04980 |
| Potassium Chloride Extended-Release | $0.13803 | +$0.04980 |
| KLOR-CON | $0.64147 | +$0.55320 |
Medicare Part D coverage · CY2026
On 328 plan formularies · typical tier 2
Prior auth 0% · Step therapy 0% · Quantity limit 0% of formularies
Sources: CMS NADAC (pharmacy acquisition cost), FDA NDC + RxNorm (identity), RxClass (therapeutic class), CMS Medicare Part D formulary (coverage). Observed reference data for professional buyers — not a retail/cash price, not pricing or medical advice. Verify before purchasing or substituting.